Adalank
Adamantane-modified anxiolytic peptide with enhanced membrane permeability and prolonged half-life
Mechanism of Action
Adalank is a structural analog of Selank with an adamantane moiety substituted at its N-terminus. This adamantylation significantly increases lipophilicity, enabling superior blood-brain barrier penetration compared to native Selank. Like Selank, Adalank modulates GABAergic neurotransmission and inhibits enkephalin-degrading enzymes, effectively prolonging endogenous opioid activity. The adamantane scaffold also confers enhanced metabolic stability, extending the compound's biological half-life and reducing the frequency of dosing required to maintain receptor engagement. Research suggests Adalank may modulate BDNF expression and reduce pro-inflammatory cytokines (IL-6, TNF-α) in neuronal tissue models.
Evidence Level
In Vitro - Cell
12 studies published
Pharmacology
Molecular Weight
~1,050 Da (est.)
Half-Life
Estimated 2–4x longer than native Selank due to adamantane scaffold
Bioavailability
Enhanced vs. Selank; adamantane moiety improves CNS penetration